In the present study, compared to the other four treatments, the triple combination treatment (iRFA + LTX-315 + anti-CTLA-4 antibody) significantly promoted the infiltration of CD8+T cells, NK cells, TNF-α+CD8+T cells, and IFN-γ+CD8+T cells, up-regulated the expression of TNF-α and INF-γ in blood, spleen, and residual tumors, and significantly raised the proportion of memory T cells (CD44+CD8+T cells) in the mice spleen, leading to an excellent tumor-inhibitory effect. This evidence concerns the gene CTLA4 and neoplasm.